18 assets in Leiomyosarcoma

Therapeutic assets addressing Leiomyosarcoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Cediranib Leiomyosarcoma	University Health Network, Toronto	P2	CCC (53)
Durvalumab Leiomyosarcoma	University Health Network, Toronto	P2	CCC (53)
Nivolumab Leiomyosarcoma	Instituto do Cancer do Estado de São Paulo	P2	CCC (53)
Olaparib Leiomyosarcoma	University Health Network, Toronto	P2	CCC (53)
Tabelecleucel Leiomyosarcoma	Pierre Fabre Medicament	P2	CCC (53)
4H-Pyrido[1,2-a]pyrimidine-2-carboxamide, N-[[2-[[(cyclobutylmethyl)amino]methyl]-1H-indol-6-yl]methyl]-4-oxo- Leiomyosarcoma	STORM Therapeutics LTD	P1/2	CC (47)
Stc-15 Leiomyosarcoma	STORM Therapeutics LTD	P1/2	CC (47)
Toripalimab Leiomyosarcoma	STORM Therapeutics LTD	P1/2	CC (47)
Docetaxel Leiomyosarcoma	OncoResponse, Inc.	P1/2	CC (45)
Immunoglobulin G4, Anti-(Human Programmed Cell Death Protein 1) (Human Monoclonal Regn2810 Heavy Chain), Disulfide With Human Monoclonal Regn2810 .Kappa.-Chain, Dimer Leiomyosarcoma	OncoResponse, Inc.	P1/2	CC (45)
Zovostotug Leiomyosarcoma	OncoResponse, Inc.	P1/2	CC (45)
Bbi-355 Leiomyosarcoma	Boundless Bio, Inc.	P1	CC (43)
Bbi-825 Leiomyosarcoma	Boundless Bio, Inc.	P1	CC (43)
Futibatinib Leiomyosarcoma	Boundless Bio, Inc.	P1	CC (43)
okn4395 Leiomyosarcoma	Epkin	P1	CC (43)
Pcna Inhibitor Aoh1996 Leiomyosarcoma	City of Hope Medical Center	P1	CC (43)
Pembrolizumab Leiomyosarcoma	Epkin	P1	CC (43)
nm32-2668 Leiomyosarcoma	Numab Therapeutics AG	P1	CC (41)